Why Ocugen Shares Are Falling

Ocugen Inc OCGN shares are trading lower by 19.6% at $3.40 Wednesday morning after the company announced pricing of a $53.5 million public offering of common stock.

Ocugen shares were otherwise rising during Tuesday's trading session after company announced the FDA lifted its clinical hold on the company's COVID-19 vaccine study in the US.

See Also: 'I'm Waiting To Catch Somebody Else's Falling Knife': Why Josh Brown Placed Limit Orders To Buy These 4 Stocks

Ocugen is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases.

Ocugen has a 52-week high of $17.65 and a 52-week low of $2.87.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: MoversTrading Ideaswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!